Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) is a leading cancer treatment and research organization focused on providing high-quality, value-based oncology care. Founded in 2007, TOI has established itself as a premier provider of comprehensive cancer treatment with over 70 clinic locations and a team exceeding 110 clinicians. The Institute offers a wide range of services, including infusion centers, outpatient blood transfusions, stem cell transplants, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.
TOI operates in three primary segments: dispensary services, patient services, and clinical trials. The core of its operations lies in patient services, where personalized care plans are developed in collaboration with patients and their families to meet their unique needs. TOI’s mission is to advance oncology by making cutting-edge, evidence-based cancer care accessible within the community setting.
In recent developments, TOI announced a strategic partnership with WellBe Senior Medical to extend its High-Value Cancer Care Program to eligible patients in Illinois and Ohio. This initiative aims to enhance patient satisfaction, reduce acute care facility utilization, and support patients throughout their cancer treatment journey. Furthermore, TOI has joined Carrum Health’s Centers of Excellence network, providing high-value oncology care to non-metastatic breast cancer patients in Las Vegas.
TOI’s commitment to innovation in oncology care is also highlighted through its strategic collaboration with Healthly, a growing healthcare company focused on preventive medicine. Starting July 2024, TOI will offer its specialized cancer care services to Healthly’s affiliated patients and physicians across Southern California. This collaboration underscores TOI’s dedication to providing accessible and comprehensive cancer care in community settings.
Financially, TOI has a strong foundation supported by revenue generated predominantly from patient services. The Institute continues to expand its influence through partnerships and value-based care agreements, ensuring a sustainable and impactful presence in the oncology landscape. For more information, please visit theoncologyinstitute.com.
The Oncology Institute (NASDAQ: TOI) is enhancing its presence in value-based oncology care. Executives will attend key conferences, including the Association for Value-Based Cancer Care from October 19-21 in New York, where CEO Brad Hively will address capital markets' impact on cancer care. Other sessions include insights from COO Dr. Matt Miller and Chief Medical Officer Dr. Yale Podnos. Dr. Daniel Virnich will also speak at the Reuters Oncology Conference on October 20. These events reflect TOI's growth and commitment to innovative oncology solutions.
The Oncology Institute announces the appointment of Phil Reger as Chief Information Officer and Cristina Green as Vice President of Clinical Research. Reger, with 25 years of IT experience including healthcare, will lead technology initiatives to support the company's growth. Green, boasting over 24 years in clinical research, will enhance access to clinical trials for patients. CEO Brad Hively emphasized the importance of their leadership in advancing TOI's focus on research and health equity. TOI aims to deliver specialized, value-based cancer care across the U.S.
The Oncology Institute (NASDAQ: TOI) has expanded into Broward County, Florida, by acquiring Broward Oncology Associates and opening a new clinic in Plantation. This strategic move strengthens TOI's presence in Florida, aligning with its value-based care model aimed at improving clinical outcomes. CEO Brad Hively expressed optimism about providing cutting-edge care to local communities. The Fort Lauderdale clinic will continue operations without disruption, while the Plantation location is set to open in mid-October 2022.
The Oncology Institute, Inc. (NASDAQ: TOI) has announced the successful enrollment of two patients in a Phase 3 clinical trial (BRUIN-CLL-314) comparing Pirtobrutinib (LOXO-305) to Ibrutinib for treating Chronic Lymphocytic Leukemia. Pirtobrutinib targets the Bruton Tyrosine Kinase with a reversible binding mechanism, potentially providing better efficacy and fewer side effects than Ibrutinib, which has been on the market since 2013. The trial is sponsored by Eli Lilly and aims to enhance treatment options for patients with recurring CLL.
The Oncology Institute, Inc. (NASDAQ: TOI) announced the addition of Mark Pacala and Gabe Ling to its Board of Directors, expanding the board to nine members. This strategic move aims to strengthen the company as it grows in the oncology sector, leveraging their deep healthcare management and investment expertise. Pacala brings over 30 years of experience in healthcare, including leadership roles at major companies, while Ling co-founded M33 Growth, focusing on emerging technology and healthcare investments. Their insights are expected to guide TOI's pursuit of its strategic objectives.
CERRITOS, Calif., Sept. 15, 2022 - The Oncology Institute, Inc. (NASDAQ: TOI) announced that its CEO, Brad Hively, will join the panel on 'Next Frontier - Value Based Care for Sub-Capitation/Specialties' at the Nephron 2nd Annual Physician Enablement Symposium on September 22 at 9:00 am EST. Founded in 2007, TOI is one of the largest value-based oncology groups in the U.S., serving around 1.7 million patients through over 50 clinic locations, employing more than 90 clinicians.
The Oncology Institute (NASDAQ: TOI) has achieved Patient Safety Organization (PSO) accreditation from the Agency for Healthcare Research and Quality. This new entity aims to enhance patient safety and care quality by analyzing safety data and providing guidance and training to clinicians. Dr. Yale Podnos, the Chief Medical Officer, emphasized that this certification underscores their commitment to patient care. Currently, only 100 PSOs exist in the U.S., with TOI obtaining a three-year listing effective August 25, 2022. This accreditation is expected to bolster the organization’s healthcare services.
The Oncology Institute (NASDAQ: TOI) partners with Blue Note Therapeutics to enhance mental health support for cancer patients. The digital therapeutic attune™ addresses anxiety and depression specifically related to cancer treatments, available via prescription to eligible TOI patients. This partnership aims to improve patient access to psychological resources, targeting the 85% of U.S. cancer patients treated in community settings. The initiative aligns with TOI's commitment to value-based care, emphasizing comprehensive support throughout patients' cancer journeys.
The Oncology Institute (NASDAQ: TOI) will host a Fireside Chat featuring CEO Brad Hively and CFO Mihir Shah during the Baird Newly Public Company Virtual Access Day on August 17, 2022, at 2:20 PM EST. Interested investors can access the live webcast through the Investor Relations section of the company’s website. The Oncology Institute focuses on advancing value-based community oncology, serving around 1.7 million patients with over 90 clinicians across 50+ locations. For further information, visit theoncologyinstitute.com.
The Oncology Institute (NASDAQ: TOI) reported a strong second quarter for 2022, with revenue at $61 million, up 22.2% year-over-year. Despite this growth, the company faced a net loss of $5 million compared to a net income of $3 million in the previous year. They completed a $110 million investment from Deerfield Management, aimed at supporting expansion. The company maintains its 2022 guidance, projecting revenue between $270 million and $310 million and an adjusted EBITDA loss of $20 to $25 million. Overall, TOI continues its growth trajectory with a focus on value-based oncology.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
What services does The Oncology Institute, Inc. provide?
Where are The Oncology Institute's clinics located?
What recent partnerships has TOI announced?
How does TOI contribute to cancer research?
What is the focus of TOI's value-based care model?
How can patients access TOI's services?
What makes TOI's High-Value Cancer Care Program unique?
Who are the primary beneficiaries of TOI's services?
What role do clinical trials play at TOI?
How does TOI support patients financially?
